Search This Blog

Thursday, January 20, 2022

U.S. preparing for possible future COVID variants -White House

 

The Biden administration is preparing for future variants of COVID-19, White House chief of Staff Ron Klain told MSNBC in an interview that aired on Thursday as the Omicron-related wave of cases appeared to be easing in parts of the country.

"We're prepared. We're increasing the production of tests. We're increasing the production of masks," Klain said in the interview that was taped on Wednesday.

"We have to be prepared for whatever comes next... there's a lot of steps left in fighting this pandemic. We are taking those steps."

https://www.marketscreener.com/quote/stock/ON-SEMICONDUCTOR-CORPORAT-10340/news/U-S-preparing-for-possible-future-COVID-variants-White-House-37597425/

New York Sued For Using Race To Help Determine Who Receives Crucial COVID-19 Treatment

 by Zachary Stieber via The Epoch Times (emphasis ours),

A legal group has filed a lawsuit against the state of New York for refusing to stop using race to help determine which people should receive monoclonal antibodies, a crucial treatment for COVID-19 that has been rationed by the federal government.

America First Legal lodged the suit after the New York State Department of Health ignored a warning over the policy.

New York’s racist COVID decrees dispense lifesaving medicine based on the race or ethnic background of the patient. New York is deciding questions of life and death based on a New Yorker’s ancestry. This is outrageously illegal, unconstitutional, immoral, and tyrannical. And that is why we are suing the state—because right and justice and morality urgently demands it,” Stephen Miller, the group’s president, said in a statement.

In a Dec. 27, 2021, directive, New York officials highlighted the “severe shortage” of monoclonal antibodies and other COVID-19 treatments and instructed providers that “non-white race or Hispanic/Latino ethnicity should be considered a risk factor, as longstanding systemic health and social inequities have contributed to an increased risk of severe illness and death from COVID-19.”

In the class-action suit, filed recently in federal court in Binghamton, plaintiff William Jacobson said the result of the directive is that white people are ineligible for the treatments unless he or she demonstrates a medical condition or risk factor that increases their risk for severe illness from COVID-19, which is the disease caused by the CCP (Chinese Communist Party) virus.

“Using a patient’s skin color or ethnicity as a basis for deciding who should receive lifesaving medical treatment is appalling. And directing medical professionals to award or deny medical care based on immutable characteristics such as skin color, without regard to the actual health condition of the individual who is seeking these antiviral treatments, is nothing more than an attempt to establish a racial hierarchy in the provision of life-saving medicine. Worse still, New York’s racial preferences ignore the obvious race-neutral alternative policy of making antiviral treatments available to patients of any race who can demonstrate risk factors, such as advanced age, obesity, a compromised immune system, or other medical conditions,” the suit says.

The New York State Department of Health and the office of Gov. Kathy Hochul, a Democrat, have not responded to requests for comment.

The Food and Drug Administration, which says that race and ethnicity are factors in determining which patients get treatments, has been urged to amend the “racist and un-American” guidance.

At least two other states had imposed policies similar to New York’s and were threatened with legal action by America First Legal.

Minnesota is using a risk score calculator that includes the same racial preferences as New York to determine which patients should get treatments in short supply.

Officials there on Jan. 11 said they were “re-evaluating the calculator” but defended the racial aspect, saying research indicated that “Hispanic/Latinx people” are 35 to 50 percent more likely to be hospitalized.

A day later, the state received notice that it may face a suit if the policy isn’t amended.

Minnesota officials, meanwhile, changed how it prioritizes treatments after Miller appeared on Fox News and said his group may sue the state.

Minnesota had been using a “monoclonal antibody screening score” that used “BIOPOC status” as a factor. BIPOC stands for black and indigenous people of color.

Officials removed mention of race from the screening score but the updated guidance says providers “may consider whether a patient has heightened risk of progression to severe COVID-19 associated with race and ethnicity when determining eligibility for mAbs,” or the antibodies.

Minnesota’s Department of Health acknowledged receipt of emailed questions about the policy but have not given answers four days later.

https://www.zerohedge.com/political/new-york-sued-using-race-help-determine-who-receives-crucial-covid-19-treatment

NovoCure upped to Buy from Hold by Truist

 Target $125

https://finviz.com/quote.ashx?t=NVCR&ty=c&ta=1&p=d

BioDelivery Sciences Sees 2021 Revenue at High End of Full Year Guidance

 Total 2021 Net Revenue expected in the range of $165 -$167 million, as compared to previous guidance of $162-$167 million

BELBUCA 2021 Net Sales expected to be in the range of $147 -$148 million, as compared to previous guidance of $144-$148 million

2021 EBITDA expected to be in the $40 - $45 million range as compared with previous guidance of <$40 million

https://finance.yahoo.com/news/biodelivery-sciences-expects-2021-revenue-130000629.html

Turning Point Cleared on Application for Lung Cancer Combo

 Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that the company has received clearance from the FDA for the company’s Investigational New Drug (IND) application for the combination of elzovantinib and aumolertinib in EGFR mutant MET-amplified advanced non-small cell lung cancer (NSCLC). The company expects to initiate the Phase 1b/2 SHIELD-2 combination study in mid-2022.

Aumolertinib is EQRx’s third generation EGFR inhibitor which is approved in China for first line treatment of EGFR mutant NSCLC and second line treatment of T790M+ EGFR mutant NSCLC. The combination of elzovantinib and aumolertinib will be studied in this Phase 1b/2 trial in patients with EGFR mutant MET-amplified advanced NSCLC who have progressed following treatment with osimertinib. The study will evaluate the safety, tolerability and preliminary efficacy of the combination regimen.

Preclinical data suggest the combination of MET and EGFR inhibition has the potential to increase anti-tumor activity based on complementary mechanisms. It is estimated that 15 to 20% of patients who progress on a first-line EGFR inhibitor develop MET amplification as the basis of acquired resistance.

https://finance.yahoo.com/news/turning-point-therapeutics-announces-fda-140000733.html

Oncolytics updates on Phase 1/2 GI cancer trial at ASCO

 Successfully enrolled first-line metastatic pancreatic and third-line metastatic colorectal safety run-ins

Company moving to full enrollment pending independent safety review

Multi-center trial being conducted in collaboration with Roche and AIO builds on prior promising data from pancreatic and colorectal cancer trials

https://finance.yahoo.com/news/oncolytics-biotech-provides-enrollment-multi-130500259.html

Tenet upped to Strong Buy from Outperform by Raymond James

 Target to $120 from $105

https://finviz.com/quote.ashx?t=THC&ty=c&ta=1&p=d